Effectiveness of adjuvant trastuzumab in daily clinical practice

Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one th...

Full description

Bibliographic Details
Main Authors:	Matos Erika, Zakotnik Branko, Kuhar Cvetka Grasic
Format:	Article
Language:	English
Published:	Sciendo 2014-12-01
Series:	Radiology and Oncology
Subjects:	breast cancer trastuzumab adjuvant daily clinical practice
Online Access:	https://doi.org/10.2478/raon-2013-0081

id	doaj-8e675d8c96f848ecab36468b46a7ece8
record_format	Article
spelling	doaj-8e675d8c96f848ecab36468b46a7ece82021-09-05T14:01:18ZengSciendoRadiology and Oncology1581-32072014-12-0148440340710.2478/raon-2013-0081raon-2013-0081Effectiveness of adjuvant trastuzumab in daily clinical practiceMatos Erika0Zakotnik Branko1Kuhar Cvetka Grasic2Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, SloveniaInstitute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, SloveniaBackground. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice.https://doi.org/10.2478/raon-2013-0081breast cancertrastuzumabadjuvantdaily clinical practice
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Matos Erika Zakotnik Branko Kuhar Cvetka Grasic
spellingShingle	Matos Erika Zakotnik Branko Kuhar Cvetka Grasic Effectiveness of adjuvant trastuzumab in daily clinical practice Radiology and Oncology breast cancer trastuzumab adjuvant daily clinical practice
author_facet	Matos Erika Zakotnik Branko Kuhar Cvetka Grasic
author_sort	Matos Erika
title	Effectiveness of adjuvant trastuzumab in daily clinical practice
title_short	Effectiveness of adjuvant trastuzumab in daily clinical practice
title_full	Effectiveness of adjuvant trastuzumab in daily clinical practice
title_fullStr	Effectiveness of adjuvant trastuzumab in daily clinical practice
title_full_unstemmed	Effectiveness of adjuvant trastuzumab in daily clinical practice
title_sort	effectiveness of adjuvant trastuzumab in daily clinical practice
publisher	Sciendo
series	Radiology and Oncology
issn	1581-3207
publishDate	2014-12-01
description	Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice.
topic	breast cancer trastuzumab adjuvant daily clinical practice
url	https://doi.org/10.2478/raon-2013-0081
work_keys_str_mv	AT matoserika effectivenessofadjuvanttrastuzumabindailyclinicalpractice AT zakotnikbranko effectivenessofadjuvanttrastuzumabindailyclinicalpractice AT kuharcvetkagrasic effectivenessofadjuvanttrastuzumabindailyclinicalpractice
_version_	1717810434849898496

Effectiveness of adjuvant trastuzumab in daily clinical practice

Similar Items